<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39436022</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1346-8138</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>22</Day></PubDate></JournalIssue><Title>The Journal of dermatology</Title><ISOAbbreviation>J Dermatol</ISOAbbreviation></Journal><ArticleTitle>The continuous increase in the number of newly medically attended cases of herpes zoster did not accelerate during the coronavirus disease 2019 pandemic in Kanagawa, Japan.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/1346-8138.17513</ELocationID><Abstract><AbstractText>Possible changes in the epidemiology of herpes zoster (HZ) since the emergence of the coronavirus disease 2019 (COVID-19) pandemic is an unfolding topic. The number of newly medically attended cases (NMAC) of HZ during the pandemic in Kanagawa Prefecture, Japan, was quantitatively investigated using a claims database. The study period was from April 2017 to March 2022. The number of NMAC of HZ showed a continuously increasing trend throughout the study period, which could be attributed to population aging. Autoregressive integrated moving average modeling and forecasting revealed that the increase in the actual number of NMAC of HZ since the start of the pandemic was generally similar to that predicted based on a model fitted using data from the pre-pandemic period, but at a slightly reduced pace. This slowdown suggests that refraining from medical visits during the pandemic affected HZ surveillance.</AbstractText><CopyrightInformation>© 2024 Japanese Dermatological Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sakamoto</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0009-0001-4433-5705</Identifier><AffiliationInfo><Affiliation>School of Health Innovation, Kanagawa University of Human Services, Kawasaki, Kanagawa, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Research, Japan Development, MSD K.K., Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watanabe</LastName><ForeName>Ryo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>School of Health Innovation, Kanagawa University of Human Services, Kawasaki, Kanagawa, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Dermatol</MedlineTA><NlmUniqueID>7600545</NlmUniqueID><ISSNLinking>0385-2407</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Japan</Keyword><Keyword MajorTopicYN="N">coronavirus disease 2019</Keyword><Keyword MajorTopicYN="N">database</Keyword><Keyword MajorTopicYN="N">epidemiology</Keyword><Keyword MajorTopicYN="N">herpes zoster</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>16</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>16</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>8</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39436022</ArticleId><ArticleId IdType="doi">10.1111/1346-8138.17513</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Koshy E, Mengting L, Kumar H, Jianbo W. Epidemiology, treatment and prevention of herpes zoster: a comprehensive review. Indian J Dermatol Venereol Leprol. 2018;84:251–262.</Citation></Reference><Reference><Citation>Patil A, Goldust M, Wollina U. Herpes zoster: a review of clinical manifestations and management. Viruses. 2022;14:192.</Citation></Reference><Reference><Citation>Kusumi E. Intense pain! Three reasons of “herpes zoster surge” under the COVID‐19 pandemic [Internet]. 2022 [cited 2024 Aug 16]. Available from: https://toyokeizai.net/articles/‐/591445</Citation></Reference><Reference><Citation>m3.com Editorial Office. Herpes zoster patients under the COVID‐19 pandemic, 1 out of 4 physicians noted “increasing” [Internet]. 2022 [cited 2024 Aug 16]. Available from: https://www.m3.com/clinical/open/news/1043900</Citation></Reference><Reference><Citation>Bhavsar A, Lonnet G, Wang C, Chatzikonstantinidou K, Parikh R, Brabant Y, et al. Increased risk of herpes zoster in adults ≥50 years old diagnosed with COVID‐19 in the United States. Open Forum Infect Dis. 2022;9:ofac118.</Citation></Reference><Reference><Citation>Shiraki K, Toyama N. Miyazaki study of herpes zoster. Mod Med. 2020;66:251–264.</Citation></Reference><Reference><Citation>Shiraki K, Toyama N, Tanaka K, Ito A, Yamamoto J. Effect of universal varicella vaccination and behavioral changes against coronavirus disease 2019 pandemic on the incidence of herpes zoster. J Dermatol Sci. 2021;104:185–192.</Citation></Reference><Reference><Citation>Nakamura H, Mizukami A, Adachi K, Matthews S, Holl K, Asano K, et al. Economic burden of herpes zoster and post‐herpetic neuralgia in adults 60 years of age or older: results from a prospective, physician practice‐based cohort study in Kushiro, Japan. Drugs Real World Outcomes. 2017;4:187–198.</Citation></Reference><Reference><Citation>Ahn SM, Eun S, Ji S, Hong S, Lee CK, Yoo B, et al. Incidence of rheumatic diseases during the COVID‐19 pandemic in South Korea. Korean J Intern Med. 2023;38:248–253.</Citation></Reference><Reference><Citation>Santiago M, Stocker F, Ministro P, Gonçalves R, Carvalho D, Portela F, et al. Incidence trends of inflammatory bowel disease in a southern European country: a mirror of the Western World? Clin Transl Gastroenterol. 2022;13:e00481.</Citation></Reference><Reference><Citation>Johnson and Johnson K.K. Medical Company. 2021 Survey on attitude and actual situation regarding medical visits such as health checkup, comprehensive medical examination and cancer screening (citizen survey) [Internet]. 2021 [cited 2024 Aug 16]. Available from: https://www.jnj.co.jp/jjmkk/healthcare‐of‐new‐normal/health‐care‐information/research/life‐2</Citation></Reference><Reference><Citation>Esri Japan Corporation. COVID‐19 vaccination status dashboard [Internet]. [cited 2024 Aug 16]. Available from: https://national‐government.esrij.com/apps/ej::%E6%96%B0%E5%9E%8B%E3%82%B3%E3%83%AD%E3%83%8A%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E6%8E%A5%E7%A8%AE%E7%8A%B6%E6%B3%81%E3%83%80%E3%83%83%E3%82%B7%E3%83%A5%E3%83%9C%E3%83%BC%E3%83%89/explore</Citation></Reference><Reference><Citation>Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid‐19 vaccine. N Engl J Med. 2020;383:2603–2615.</Citation></Reference><Reference><Citation>Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA‐1273 SARS‐CoV‐2 vaccine. N Engl J Med. 2021;384:403–416.</Citation></Reference><Reference><Citation>Ministry of Health, Labour and Welfare. Visualizing the data: information on COVID‐19 infections [Internet]. 2023 [cited 2024 Aug 16]. Available from: https://covid19.mhlw.go.jp/en/</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>